Posted by Michael Wonder on 23 Dec 2017
Many FDA approved cancer drugs might lack clinical benefit
21 December 2017 - New research shows that less than half of the randomised controlled trials that support the approval of anticancer drugs by the US FDA reach the threshold for clinical benefit as defined by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale.
